相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Reversal of antithrombotic agents
Kenneth A. Bauer
AMERICAN JOURNAL OF HEMATOLOGY (2012)
A Case Series of Recombinant Platelet Factor 4 for Heparin Reversal After Cardiopulmonary Bypass
Linda Demma et al.
ANESTHESIA AND ANALGESIA (2012)
Treatment and Prevention of Heparin-Induced Thrombocytopenia Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Lori-Ann Linkins et al.
CHEST (2012)
Heparin-Induced Thrombocytopenia: An Update
Margaret Prechel et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2012)
Prognostic importance of preoperative anti-PF4/heparin antibodies in patients undergoing cardiac surgery A systematic review
Arif M. Yusuf et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Emergency reversal of pentasaccharide anticoagulants: a systematic review of the literature
J. Elmer et al.
TRANSFUSION MEDICINE (2012)
Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives
Elsa P. Bianchini et al.
BLOOD (2011)
Protamine sulfate stimulates degradation of factor Xa and the factor Xa-antithrombin complex
Martin H. Coggin et al.
BLOOD COAGULATION & FIBRINOLYSIS (2011)
Muscle Creatine Kinase Deficiency Triggers Both Actin Depolymerization and Desmin Disorganization by Advanced Glycation End Products in Dilated Cardiomyopathy
Nicolas Diguet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Reply to A comment on laboratory monitoring of new anticoagulants
Donna D. Castellone et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonist
Daniel J. Cushing et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2010)
Reaction of the Butter Flavorant Diacetyl (2,3-Butanedione) with N-α-Acetylarginine: A Model for Epitope Formation with Pulmonary Proteins in the Etiology of Obliterative Bronchiolitis
James M. Mathews et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2010)
Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke
Mohamed Salem et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation
Fionnuala Ni Ainle et al.
BLOOD (2009)
Effect of citrullination on the function and conformation of antithrombin
A. Ordonez et al.
FEBS JOURNAL (2009)
Serious anaphylactic reactions due to protamine sulfate: A systematic literature review
Mads Nybo et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2008)
Protamine inhibits formation of the covalent factor IXa-anti-thrombin complex
Arthur S. Brecher et al.
BLOOD COAGULATION & FIBRINOLYSIS (2008)
Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors
T. Abshire et al.
HAEMOPHILIA (2008)
Outbreak of Adverse Reactions Associated with Contaminated Heparin
David B. Blossom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Fondaparinux: Pharmacology and clinical experience in cardiovascular medicine
V. Toschi et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2007)
Efficacy and safety of heparinase I versus protamine in patients undergoing coronary artery bypass grafting withl and without cardiopulmonary bypass
M Stafford-Smith et al.
ANESTHESIOLOGY (2005)
Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo
BP Schick et al.
BLOOD (2004)
Deletion of P1 arginine in a novel antithrombin variant (antithrombin london) abolishes inhibitory activity but enhances heparin affinity and is associated with early onset thrombosis
SM Raja et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Catastrophic cardiovascular adverse reactions to protamine are nitric oxide/cyclic guanosine monophosphate dependent and endothelium mediated - Should methylene blue be the treatment of choice?
F Viaro et al.
CHEST (2002)
The antithrombin P1 residue is important for target proteinase specificity but not for heparin activation of the serpin. Characterization of P1 antithrombin variants with altered proteinase specificity but normal heparin activation
YJ Chuang et al.
BIOCHEMISTRY (2001)
分享论文
